Differential in Vitro Response of the Human Radial Artery Versus Left Internal Thoracic Artery to Cerivastatin: Implications to Bypass Grafting

Annals of Thoracic Surgery

Volumn 76, Issue 6, 2003, Pages 2023-2028

  Nakamura, Koki ^a   Al Ruzzeh, Sharif ^a   Chester, Adrian H ^a   Ilsley, Charles ^a   Yacoub, Magdi H ^a   Amrani, Mohamed ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CERIVASTATIN; ENDOTHELIN 1;

ADULT; ARTICLE; BYPASS SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY SURGERY; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIAL ARTERY; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

EID: 0345527898     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)01297-9     Document Type: Article

References (24)

1. Carpentier A, Guermonprez JL, Deloche A, Frechette C, DuBost C. The aorta-to-coronary radial artery bypass graft. Ann Thorac Surg 1973;16:111-21.
2. Acar C, Jebara VA, Portoghese M, et al. Revival of the radial artery for coronary artery bypass grafting. Ann Thorac Surg 1992;54:652-60.
3. Reyes AT, Frame R, Brodman RF. Technique for harvesting the radial artery as a coronary artery bypass graft. Ann Thorac Surg 1995;59:118-26.
4. Acar C, Ramsheyi A, Pagny JY, et al. The radial artery for coronary artery bypass grafting: clinical and angiographic results at five years. J Thorac Cardiovasc Surg 1998;116: 981-9.
5. Dzimiri N, Chester AH, Allen SP, Duran C, Yacoub MH. Vascular reactivity of arterial coronary artery bypass grafts - Implications for their performance. Clin Cardiol 1996;19: 165-71.
6. Laufs U, La Fata V, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997;272:31725-9.
7. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001;37:1351-8.
8. Yang Z, Kozai T, van de Loo B, et al. HMG-CoA reductase inhibition improves endothelial cell function, and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000;36:1691-7.
9. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
10. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect. Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary endothelial cells. Life Sci 2000;67:863-76.
11. González-Fernández F, Jiménez A, López-Blaya A, et al. Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis 2001;155:61-70.
12. Campeau L. Lipid lowering and coronary bypass graft surgery. Curr Opin Cardiol 2000;15:395-9.
13. Chester AH, Marchbank AJ, Borland JAA, Yacoub MH, Taggart DP. Comparison of the morphologic and vascular reactivity of the proximal and distal radial artery. Ann Thorac Surg 1998;66:1972-7.
14. Nakamura K, Al-Ruzzeh S, Chester AH, et al. Effects of cerivastatin on vascular function of human radial and left internal thoracic arteries. Ann Thorac Surg 2002;73:1860-5.
15. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57: 357-64.
16. Bischoff H, Angerbauer R, Bender J, et al. Cerivastatin. pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997;135:119-30.
17. von Keutz E, Schlüter G. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. Am J Cardiol 1998;82:11J-17J.
18. Bischoff H, Heller AH. Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol 1998;82:18J-25J.
19. Chester AH, Amrani M, Borland JAA. Vascular biology of the radial artery. Curr Opin Cardiol 1998;13:447-52.
20. van Son JAM, Smedts F, Vincent JG, van Lier HJJ, Kubat K. Comparative anatomic studies of various arterial conduits for myocardial revascularization. J Thorac Cardiovasc Surg 1990;99:703-7.
21. Chardigny CI, Van der Perre K, Simonet S, Descombes JJ, Fabiani JN, Verbeuren TJ. Platelets and prostacyclin in arterial bypasses: implications for coronary artery surgery. Ann Thorac Surg 2000;69:513-9.
22. Kaufer E, Factor SM, Frame R, Brodman RF. Pathology of the radial and internal thoracic arteries used as coronary artery bypass grafts. Ann Thorac Surg 1997;63:1118-22.
23. Kane-Toddhall SMB, Taggart DP, Clements-Jewery H, Roskell DE. Pre-existing vascular disease in the radial artery and other coronary artery bypass conduits. Eur J Med Res 1999;4:11-4.
24. Di Napoli P, Taccardi AA, Grilli A, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 2001;51:283-93.